

### This week in techniques

Approach	Summary	Licensing status	Publication and contact information
<b>Disease models</b>			
Bioluminescent mouse model of HPV+ oral tumors to track the effect of therapeutics	<p>A bioluminescent mouse model of HPV+ oral tumors could help evaluate potential therapeutic candidates. In mice with inducible expression of the HPV oncogenes <i>E6 transforming protein (human papillomavirus-16; HpV16gp1)</i> and <i>E7 transforming protein (human papillomavirus-16; HpV16gp2)</i> and luciferase, oncogenic K-Ras (Kras) expression in the epithelia induced the development of oral tumors with enhanced bioluminescence that correlated with tumor growth. In the mouse model, rapamycin or image-guided radiotherapy induced tumor regression and decreased bioluminescence at least threefold compared with vehicle or no irradiation. Next steps could include using the model to test preclinical therapeutic candidates.</p> <p>Rapamycin is a generic small molecule inhibitor of mammalian target of rapamycin (mTOR; FRAP; RAFT1).</p> <p><b>SciBX 7(13); doi:10.1038/scibx.2014.381</b>  <b>Published online April 3, 2014</b></p>	Patent and licensing status unavailable	<p>Zhong, R. <i>et al. Cancer Res.</i>; published online Feb. 13, 2014;            doi:10.1158/0008-5472.CAN-13-2993  <b>Contact:</b> Michael Spiotto, The University of Chicago, Chicago, Ill.            e-mail:  <a href="mailto:mspiotto@radonc.uchicago.edu">mspiotto@radonc.uchicago.edu</a></p>